Physician profile
David Eugene Spivey
NPI 1467413054
$1,118.31
in general payments reported to CMS, 2019-2025
19 companies · $133 in 2025
The $133 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $199 · 2020: $51.18 · 2021: $42.44 · 2022: $92.40 · 2023: $194 · 2024: $406 · 2025: $133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $734.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $733.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $198.87 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbott Laboratories | $169.32 | 2022-2024 | Freestyle Libre 3 |
| Amgen INC. | $154.34 | 2019-2025 | Repatha, Otezla, Evenity |
| Pfizer INC. | $82.50 | 2019-2022 | |
| Abbvie INC. | $81.83 | 2023-2024 | Vraylar, Ubrelvy |
| Medtronic, INC. | $59.70 | 2024-2025 | Inceptiv, Intellis Adaptivestim |
| Janssen Pharmaceuticals, INC | $58.66 | 2019-2021 | |
| Boston Scientific Corporation | $45.65 | 2024 | Wavewriter Alpha Prime 16 |
| Lilly USA, LLC | $43.08 | 2024-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $42.53 | 2019-2021 | |
| Bausch Health US, LLC | $38.60 | 2019-2024 | Aplenzin, Wellbutrin |
| Gilead Sciences, INC. | $26.69 | 2024 | |
| Rhythm Pharmaceuticals, INC. | $25.33 | 2023 | Imcivree |
| Vertos Medical, INC. | $20.78 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $18.00 | 2023 | Rexulti |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sonex Health, INC. | $16.02 | 2024 | Sx-One Microknife |
| Amarin Pharma, INC. | $13.33 | 2019 | |
| Merck Sharp & Dohme LLC | $11.70 | 2019 | |
| Glaxosmithkline, LLC. | $11.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Spivey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.